GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chimeric Therapeutics Ltd (ASX:CHM) » Definitions » Long-Term Debt

Chimeric Therapeutics (ASX:CHM) Long-Term Debt : A$0.00 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Chimeric Therapeutics Long-Term Debt?

Chimeric Therapeutics's Long-Term Debt for the quarter that ended in Dec. 2023 was A$0.00 Mil.

Chimeric Therapeutics Long-Term Debt Historical Data

The historical data trend for Chimeric Therapeutics's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chimeric Therapeutics Long-Term Debt Chart

Chimeric Therapeutics Annual Data
Trend Jun21 Jun22 Jun23
Long-Term Debt
- - -

Chimeric Therapeutics Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Long-Term Debt Get a 7-Day Free Trial - - - - -

Chimeric Therapeutics  (ASX:CHM) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Chimeric Therapeutics Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Chimeric Therapeutics's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Chimeric Therapeutics (ASX:CHM) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chimeric Therapeutics Ltd (ASX:CHM) » Definitions » Long-Term Debt
Comparable Companies
ASX:TRP ASX:VBS ASX:IMC ASX:PAB ASX:ATX ASX:KZA ASX:ATH ASX:IXC ASX:BGT ASX:ACR OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
CHMMF:USA
Address
62 Lygon Street, Level 3, Carlton South, Melbourne, VIC, AUS, 3053
Website
https://www.chimerictherapeutics.com
Chimeric Therapeutics Ltd is a biotechnology company engaged in developing a cancer cell therapy drug. Its technology CLTX-CAR T uses chlorotoxin, a peptide discovered in scorpion venom, as the tumor-targeting component of the CAR to reprogram T cells. Primary products under development by the company are NK Cell Derived Allogenic Therapies and T Cell Derived Autologous Therapies. The company has one segment being the research, development and commercialization of health technologies.

Chimeric Therapeutics (ASX:CHM) Headlines

No Headlines